Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.
Teitel
J M
JM
St Michael's Hospital, University of Toronto, Ontario, Canada.
D001779:Blood Coagulation Factors / Q000191:economics / Q000276:immunology / Q000592:standards / Q000627:therapeutic use*; D003257:Consumer Product Safety; D003365:Costs and Cost Analysis; D015942:Factor VIIa / Q000191:economics / Q000592:standards / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007518:Isoantibodies / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000191:economics / Q000592:standards / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D007518:Isoantibodies; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa